We are a privately held, pre-commercial biotech company focused on the development and commercialization of a highly effective therapy for serious skin and soft tissue infections, including those caused by antibiotic-resistant organisms such as Methicillin-resistant Staphylococcus aureus (MRSA), based on a disruptive new drug delivery technology called Ultrasonic Drug Disperson (UDD).
Soft tissue infections are a major global health issue. When an inadequate concentration of antibiotic is used to treat a given infection, antibiotic resistant strains of bacteria develop that are increasingly difficult to treat. Patients with MRSA cellulitis of the lower extremity, especially those with impaired circulation, such as diabetics, are even more difficult to treat with standard delivery methods of antibiotics because an adequate concentration of antibiotic cannot be delivered to the target tissues.
We are conducting FDA and IRB approved research devoted to determining whether ultrasonic dispersion of infused antibiotics into a target area is more effective than traditional intravenous administration.